Haemaflow was established in 2008 to develop inventions arising from the Haemair work on supporting people with lung disease or lung damage. Currently, Haemaflow is 100% owned by Haemair Ltd, but trades independently. Products in the Haemaflow portfolio include:
Products in the Haemaflow portfolio include: a novel pulsatile blood pump, devices to improve blood transfusion, a novel point-of-care rheometer to assess the propensity of blood to clot (to improve assessing coagulants and anticoagulants and as a possible early marker for Sepsis), developments that may improve the quality of transplant organs, and a gas or liquid analyser that does not require samples to be taken.